GEN-MKT-18-7897-A
Feb 12, 2025 | Blogs, Discovery, Echo® MS+ system, Pharma, QA/QC | 0 comments
Read time: 2 minutes
On average, it takes 10-15 years and 1-2 billion dollars to approve a new pharmaceutical for clinical use. Since approximately 90% of new drug candidates fail in clinical development, the ability to make early, informed and accurate decisions on the safety and efficacy of new hits and leads is key to increasing the chances of success.
To achieve this drug discovery assays require speed and accuracy, but often scientists must compromise on one of these requirements to cope with the thousands of samples that need to be analyzed.
The Echo® MS+ system allows pharmaceutical companies to make data-driven decisions early in the drug discovery process, saving time and money, and potentially getting their drug to market faster than with more traditional approaches. Common analytical techniques such as LC-MS or fluorescence are limited by either sample throughput or accuracy of results.
Learn more >
The Echo® MS+ system uses acoustic ejection mass spectrometry (AEMS) technology. Samples are placed into a compatible well plate which is held in the Echo® MS+ system’s autosampler. Here sound energy is applied to the bottom of each well individually. The sound energy causes reproducible droplets to be ejected from the well for capture in a carrier solvent of the OPI for dilution and transfer to the mass spectrometer’s source. From this point, the diluted sample is ionized using conventional electrospray ionization, ready for detection.
Watch video >
In monoclonal antibody (mAb) development, assessment of purity and integrity of the protein in question is critical. CE‑SDS is the gold standard assay and is routinely run from analytical development through QC and lot release. It’s trusted because it consistently delivers quantitative, size‑based insight into purity and fragmentation, and it fits naturally into regulated environments.
In drug discovery and development, Metabolite Identification (Met ID) plays a critical role in understanding biotransformation pathways, ensuring safety, and meeting regulatory requirements. Advanced mass spectrometry techniques have revolutionized this process, particularly through electron-based fragmentation methods such as Electron Activated Dissociation (EAD) and Electron Transfer Dissociation (ETD). While both techniques leverage electron interactions to generate informative fragment ions, they differ significantly in mechanism, performance, and suitability for Met ID workflows.
In analytical laboratories, performance is not optional. Whether supporting regulated pharmaceutical workflows, high-throughput CRO operations, clinical reporting, or food and environmental testing, your mass spectrometry and capillary electrophoresis systems are critical to productivity, compliance, and scientific confidence.
Posted by
You must be logged in to post a comment.
Share this post with your network